Pharmaceutical Companies

AGC Biologics now offers the ATUM transposase-based platform as part of its growing portfolio of cell line development solutions.

The two pharmaceutical giants originally signed the agreement in October 2025, establishing a framework centered on bispecific antibodies and ADCs.

The therapy delivers the full-length human frataxin gene using a dual-administration approach that combines direct intradentate nucleus (IDN) injection with intravenous (IV) infusion.

Itvisma works by delivering a functional copy of the survival motor neuron 1 (SMN1) gene through a single, fixed-dose intrathecal injection.

WT-7695, a preclinical radiopharmaceutical targeting carbonic anhydrase IX (CA9), was developed in collaboration with the University of Wisconsin-Madison, and SK now holds exclusive worldwide rights to develop, manufacture, and market the drug.

The project, supported by Tariq Almutlaq, Chairman of Daikin Saudi Arabia and a longtime partner, aims to localize production for key HVAC components, including chillers and hydronic heat pumps designed for sophisticated cooling requirements.

GEN1160 now joins GEN1107 on Genmab’s list of discontinued assets from the April 2024 ProfoundBio acquisition.

A company spokesperson explained that Moderna has “prioritized our pipeline and R&D investments as part of our broader cost efficiency efforts,” though the company provided no additional details about the specific discontinuations.

Through this partnership, Merck gains access to Valo’s advanced AI-powered human causal biology and discovery platforms, which the drugmaker will use to identify new disease targets and develop preclinical compounds.

The company’s Pharma business unit led the strong performance, delivering sales growth of 32%, including 20% organic growth.